Tumor

Oncology
16
Pipeline Programs
10
Companies
23
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 13 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
Tapentadol Extended ReleasePhase 35 trials
Active Trials
NCT01631513Withdrawn0Est. Apr 2013
NCT02019485Completed64Est. Aug 2010
NCT01124604Completed91Est. Dec 2010
+2 more trials
CT
3 programs
2
1
AnlotinibPhase 2Small Molecule1 trial
TQ-B3233Phase 11 trial
TQB2450Phase 11 trial
Active Trials
NCT03453034UnknownEst. Dec 2018
NCT03460457UnknownEst. Mar 2019
NCT01874873CompletedEst. Dec 2016
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
3 programs
3
NKTR-102Phase 21 trial
NKTR-102 100 mg/m2Phase 21 trial
NKTR-102 q14dPhase 21 trial
Active Trials
NCT00802945CompletedEst. Jan 2012
NCT00598975CompletedEst. Dec 2011
NCT00806156CompletedEst. Jan 2013
SpringWorks Therapeutics
1 program
1
NirogacestatPhase 2Small Molecule1 trial
Active Trials
NCT05879146RecruitingEst. Jan 2028
H
HutchmedChina - Hong Kong
3 programs
3
FruquintinibPhase 1Small Molecule1 trial
SulfatinibPhase 1Small Molecule1 trial
VolitinibPhase 1Small Molecule1 trial
Active Trials
NCT01645215Completed40Est. Oct 2012
NCT02133157Completed71Est. Oct 2014
NCT01773018Completed47Est. May 2016
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
3 programs
3
QL1101Phase 11 trial
QL2107Phase 11 trial
QL2109Phase 11 trial
Active Trials
NCT06232902CompletedEst. Nov 2024
NCT06173011UnknownEst. Jul 2024
NCT06371534RecruitingEst. Apr 2025
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD6244Phase 11 trial
Active Trials
NCT00463814Active Not Recruiting58Est. Dec 2025
E
EisaiChina - Liaoning
1 program
1
Eribulin mesylatePhase 11 trial
Active Trials
NCT03002493Completed14Est. Jun 2011
Ambu
AmbuDenmark - Ballerup
1 program
BronchoscopyN/A1 trial
Active Trials
NCT04770675CompletedEst. Dec 2021
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
organ motionN/A1 trial
Active Trials
NCT02095236Withdrawn0

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Johnson & JohnsonTapentadol Extended Release
Johnson & JohnsonTapentadol Extended Release
Johnson & JohnsonTapentadol Extended Release
SpringWorks TherapeuticsNirogacestat
Chia Tai TianQing Pharmaceutical GroupAnlotinib
Johnson & JohnsonTapentadol Extended Release
Nektar TherapeuticsNKTR-102
Nektar TherapeuticsNKTR-102 q14d
Nektar TherapeuticsNKTR-102 100 mg/m2
Johnson & JohnsonTapentadol Extended Release
Qilu PharmaceuticalQL1101
Qilu PharmaceuticalQL2109
Qilu PharmaceuticalQL2107
Chia Tai TianQing Pharmaceutical GroupTQB2450
Chia Tai TianQing Pharmaceutical GroupTQ-B3233

Showing 15 of 22 trials with date data

Clinical Trials (23)

Total enrollment: 1,724 patients across 23 trials

NCT01631513Johnson & JohnsonTapentadol Extended Release

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Start: Aug 2012Est. completion: Apr 20130
Phase 4Withdrawn
NCT01063868Johnson & JohnsonTapentadol Extended Release

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Start: Jan 2010Est. completion: Jun 201047 patients
Phase 3Terminated
NCT00472303Johnson & JohnsonTapentadol Extended Release

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Start: Jul 2007Est. completion: Jun 2012622 patients
Phase 3Completed

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Start: Nov 2024Est. completion: Jan 2028
Phase 2Recruiting

A Phase II Study of Anlotinib in MTC Patients

Start: Apr 2013Est. completion: Dec 2016
Phase 2Completed
NCT01124604Johnson & JohnsonTapentadol Extended Release

An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

Start: Apr 2010Est. completion: Dec 201091 patients
Phase 2Completed

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Start: Oct 2008Est. completion: Jan 2012
Phase 2Completed

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Start: Oct 2008Est. completion: Jan 2013
Phase 2Completed

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Start: Feb 2008Est. completion: Dec 2011
Phase 2Completed
NCT00745069Johnson & JohnsonTapentadol Extended Release

Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis

Start: Jul 2004Est. completion: Aug 2005670 patients
Phase 2Completed

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Start: Jun 2024Est. completion: Nov 2024
Phase 1Completed

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

Start: Apr 2024Est. completion: Apr 2025
Phase 1Recruiting

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Start: Dec 2023Est. completion: Jul 2024
Phase 1Unknown

Tolerance and Pharmacokinetics of TQB2450

Start: Mar 2018Est. completion: Mar 2019
Phase 1Unknown

Tolerance and Pharmacokinetics of TQ-B3233

Start: Nov 2017Est. completion: Dec 2018
Phase 1Unknown

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Start: Feb 2012Est. completion: May 201647 patients
Phase 1Completed

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Start: Jan 2011Est. completion: Oct 201240 patients
Phase 1Completed
NCT02019485Johnson & JohnsonTapentadol Extended Release

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Start: Jul 2010Est. completion: Aug 201064 patients
Phase 1Completed

Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Start: Apr 2010Est. completion: Oct 201471 patients
Phase 1Completed
NCT03002493EisaiEribulin mesylate

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Start: Dec 2009Est. completion: Jun 201114 patients
Phase 1Completed

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Start: Mar 2007Est. completion: Dec 202558 patients
Phase 1Active Not Recruiting

Evaluation of Intrafractional Motion of Liver Tumors Using Markers

0
N/AWithdrawn
NCT04770675AmbuBronchoscopy

Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.

Start: Dec 2020Est. completion: Dec 2021
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,724 patients
10 companies competing in this space